The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
Commenced operations in flood-affected Himachal Pradesh
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Subscribe To Our Newsletter & Stay Updated
